Study of specific pharmacological activity of standardized composition of bee product substances for treatment of urogenital system

Abstract

Introduction. The work presents review of the data literature, which indicate the prospects of creation new highly efficient drugs for the treatment of chronic prostatitis and prostate gland adenoma based bioactive standardized substances of bee products, including powdered honey (PH), propolis phenolic hydrophobic drug (PPHD) and bee pollen (BP).

Materials and methods. Results of discussion of preclinical pharmacological studies of standardized substances of bee products composition – PH, PPHD and BP for the treatment of specified pathology is given in the experimental part.

Results. It was found that the most pronounced anti-inflammatory effect on the level 40 % the mixture of APIs (PH, PPHD and BP) detects at a dose of 100 mg/kg in relation to the reference drug – trianom capsules in doses of 100 and 130 mg/kg.

Conclusions. Usage of bee products is grounded in creation of the new drug on their basis in the form of standardized substances of bee products composition –PH, PPHD and BP for chronic prostatitis and prostate gland adenoma. It was found that the most pronounced anti-inflammatory effect on 40 % the mixture of APIs (PH, PPHD and BP) detects at a dose of 100 mg/kg. It was established that the composition of standard substances of bee products – PH, PPHD and BP at a dose of 100 mg/kg shows a more pronounced specific pharmacological effect in comparison to the reference product – trianom capsules at doses of 100 and 130 mg/kg, which positively affect the course of the pilot prostatitis in male rats caused by dichloroethyl.

Full text

642
Запорожский медицинский журнал. Том 19, № 5(104), сентябрь–октябрь 2017 г.ISSN 2306-4145 http://zmj.zsmu.edu.ua
Study of specic pharmacological activity of standardized composition
of bee product substances for treatment of urogenital system
V. M. Koval1, O. I. Tykhonov2, О. S. Shpychak2
1National Pirogov Memorial Medical University, Vinnytsia, Ukraine, 2National University of Pharmacy, Kharkiv, Ukraine
Introduction. The work presents review of the data literature, which indicate the prospects of creation new highly ecient drugs
for the treatment of chronic prostatitis and prostate gland adenoma based bioactive standardized substances of bee products,
including powdered honey (PH), propolis phenolic hydrophobic drug (PPHD) and bee pollen (BP).
Materials and methods. Results of discussion of preclinical pharmacological studies of standardized substances of bee products
composition – PH, PPHD and BP for the treatment of specied pathology is given in the experimental part.
Results. It was found that the most pronounced anti-inammatory eect on the level 40 % the mixture of APIs (PH, PPHD
and BP) detects at a dose of 100 mg/kg in relation to the reference drug – trianom capsules in doses of 100 and 130 mg/kg.
Conclusions. Usage of bee products is grounded in creation of the new drug on their basis in the form of standardized
substances of bee products composition –PH, PPHD and BP for chronic prostatitis and prostate gland adenoma. It was
found that the most pronounced anti-inammatory eect on 40 % the mixture of APIs (PH, PPHD and BP) detects at a
dose of 100 mg/kg. It was established that the composition of standard substances of bee products – PH, PPHD and BP at
a dose of 100 mg/kg shows a more pronounced specic pharmacological eect in comparison to the reference product –
trianom capsules at doses of 100 and 130 mg/kg, which positively aect the course of the pilot prostatitis in male rats caused
by dichloroethyl.
Дослідження специфічної фармакологічної дії композицій стандартизованих субстанцій
продуктів бджільництва для лікування захворювань органів сечостатевої системи
В. М. Коваль, О. І. Тихонов, О. С. Шпичак
У роботі наведені дані огляду фахових літературних джерел, що свідчать про перспективність створення нових високо-
ефективних лікарських засобів для лікування хронічних простатитів та аденоми передміхурової залози на основі біоло-
гічно активних стандартизованих субстанцій продуктів бджільництва, зокрема меду порошкоподібного (МП), фенольного
гідрофобного препарату прополісу (ФГПП) та обніжжя бджолиного (ОБ).
Матеріали та методи. В експериментальній частині представлені результати обговорення доклінічних фармакологічних
досліджень композиції стандартизованих субстанцій продуктів бджільництва – МП, ФГПП та ОБ для лікування вказаної
патології.
Результати. Згідно з результатами досліджень, встановлено, що найвираженішу протизапальну дію на рівні 40 % суміш
АФІ (МП, ФГПП та ОБ) виявляє у дозі 100 мг/кг щодо референс-препарату – капсул тріаном у дозах 100 та 130 мг/кг.
Висновки. Обґрунтовано використання продуктів бджільництва для створення на їх основі нового лікарського препарату
у формі композиції стандартизованих субстанцій продуктів бджільництва – МП, ФГПП та ОБ для лікування хронічних
простатитів та аденоми статевої залози. Встановлено, що найбільш виражену протизапальну дію на рівні 40 % суміш
АФІ (МП, ФГПП та ОБ) виявляє у дозі 100 мг/кг. Встановлено, що композиція стандартизованих субстанцій продуктів
бджільництва – МП, ФГПП та ОБ у дозі 100 мг/кг проявляє набагато вираженішу специфічну фармакологічну дію щодо
референс-препарату – капсул тріаном у дозах 100 та 130 мг/кг, що позитивно впливає на перебіг експериментального
простатиту в щурів-самців, котрий викликаний дихлоретилом.
Исследование специфического фармакологического действия
композиции стандартизированных субстанций продуктов пчеловодства
для лечения заболеваний органов мочеполовой системы
В. Н. Коваль, А. И. Тихонов, О. С. Шпичак
В работе приведены данные обзора научных литературных источников, которые свидетельствуют о перспективности
создания новых высокоэффективных лекарственных средств для лечения хронических простатитов и аденомы пред-
стательной железы на основе биологически активных стандартизированных субстанций продуктов пчеловодства, в част-
ности мёда порошкообразного (МП), фенольного гидрофобного препарата прополиса (ФГПП) и пчелиной обножки (ОБ).
Материалы и методы. В экспериментальной части представлены результаты обсуждения проведённых доклинических
фармакологических исследований композиции стандартизированных субстанций продуктов пчеловодства – МП, ФГПП
и ОБ для лечения данной патологии.
Результаты. По результатам исследований установлено, что наиболее выраженный противовоспалительный эффект
на уровне 40 % смесь АФИ (МП, ФГПП и ОБ) обнаруживает в дозе 100 мг/кг по отношению к референт-препарату –
капсулам трианом в дозе 100 и 130 мг/кг.
Ключові слова:
захворювання
органів
сечостатевої
системи,
мед, прополіс,
обніжжя бджолине,
апітерапія.
Запорізький
медичний
журнал. – 2017. –
Т. 19, № 5(104). –
С. 642–646
Key words:
genitourinary
system, honey,
propolis, bee
pollen, apitherapy.
Zaporozhye
medical journal
2017; 19 (5), 642–646
DOI:
10.14739/2310-1210.
2017.5.110237
E-mail:
koval_vm@ukr.net,
shpichak_oleg@ukr.net
Ключевые слова:
заболевания
органов
мочеполовой
системы,
мёд, прополис,
обножки пчелиные,
апитерапия.
Запорожский
медицинский
журнал. – 2017. –
Т. 19, № 5(104). –
С. 642–646
UDC: 615.254
: 638.16 : 638.135 : 638.138
Оригинальные исследования

643
Zaporozhye medical journal. Volume 19. No. 5, September–October 2017 ISSN 2306-4145 http://zmj.zsmu.edu.ua
Выводы. Обосновано использование продуктов пчеловодства для создания на их основе нового лекарственного пре-
парата в форме композиции стандартизированных субстанций продуктов пчеловодства – МП, ФГПП и ОБ для лечения
хронических простатитов и аденомы половой железы. Установлено, что наиболее выраженное противовоспалительное
действие на уровне 40 % смесь АФИ (МП, ФГПП и ОБ) обнаруживает в дозе 100 мг/кг. Установлено, что композиция стан-
дартизированных субстанций продуктов пчеловодства – МП, ФГПП и ОБ в дозе 100 мг/кг проявляет более выраженное
специфическое фармакологическое действие по отношению к референт-препарату – капсулам трианом в дозе 100 и 130
мг/кг, что положительно влияет на течение экспериментального простатита у крыс-самцов, вызванного дихлорэтилом.
Introduction
In the current conditions in the treatment of the genitourinary
system diseases prostatitis is one of the most common disea-
ses in men of reproductive age [1]. For example, according to
the urology service of Ukraine chronic prostatitis now aects
about 30–45 % of men, of which almost 80 % are patients aged
21 to 56 years, and 60–75 % are of age 31 to 50 years [2].
Wide distribution of the disease indicates insucient study of its
etiology and pathogenesis, steady progress, and the lack of ef-
fective schemes and methods of diagnosis and treatment [3].
Usually, prostatitis, which is an inammation (swelling)
of the prostate gland tissue is characterized by a steady
progress, with exacerbation of which patients complain of con-
stant pain in the abdomen, urinary disorders, sexual function
(sexual dysfunction), ejaculation and changes in the quantity
and quality of the last [4]. The appearance of these symptoms
is usually associated with infection, sexually transmitted
diseases, immunity disorders, frequent hypothermia, stress,
allergic violation status, hormonal imbalance et al., the further
development of which in some cases leads to the formation
of chronic forms, accompanied by corresponding consequenc-
es and prolonged treatment [1,3,4].
Pharmacotherapy of prostatitis depends largely on the se-
verity of the disease, its duration and disturbances of sexual
function. Etiological factors (infection, hormonal disorders) are
critical in choosing specic ways of treatment. In this regard, at
this pathology nitrofuran derivatives, nevyhramon, antibiotics
are usually prescribed from the number of drugs, taking into
consideration the sensitivity of microora, sown from pros-
tate secretions. In addition, one of the basic drugs of natural
origin – prostatilen is also successfully used the treatment
of patients with prostatitis [5], the active ingredient of which
is selected from of the prostate gland of bulls, which is a
combination of proteins that, like other citomedines, are able
to inuence the state of the main hemostasis systems.
Recently, considerable attention is given to wide applica-
tion of bee products in the treatment of prostatitis and prostate
gland adenoma [6–8], in particular, natural honey, propolis
and bee pollen (ower pollen) (BP), and their standardized
substances and ocinal drugs in combination with chemo- and
phytodrugs. It is considered that the use apiproducts and their
agents in the diseases of the genitourinary system is a very
important component of drug therapy as biologically active
compounds have several advantages over synthetic drugs
and due to their complex structure contribute versatile eects
on macro organism.
Honey is a natural complex of biologically active substan-
ces, similar in composition to blood plasma, and, therefore, it
shows high healing properties. First of all, valuable medicinal
and nutritional properties of honey are caused by its com-
position containing 200 important for the body substances:
carbohydrates, proteins, enzymes, amino acids, vitamins,
minerals and others. However, the content of biologically active
compounds in dierent types of honey can vary depending
on several factors, therefore, natural honey requires standar-
dization for its introduction into medical practice.
Another value is a propolis and its compounds. Propolis
is a glue collected by bees from buds of trees and grass that
bees use to strengthen and disinfection of their hundreds.
Propolis is a complex multicomponent system of biologically
active substances, which includes more than 50 dierent
in nature substances. The main groups of propolis is resin,
balms, essential oils and waxes, as well as minerals, vitamins,
amino acids (8 to 17) and others. It was found that avonoids
takes more than 25 % among all components of propolis [7].
Preparations of propolis exhibit a wide range of biological
activities: antimicrobial, regenerating, immune-stimulating, an-
ti-inammatory, reparative, wound healing, hepatoprotective,
membrane stabilizing [9–11]. Due to its multidirectional phar-
macological action, its usage is possible in urology, especially
for the treatment of prostatitis and prostate gland adenoma
[7]. In this regard, among the number of standardized propo-
lis substances, special attention deserve propolis phenolic
hydrophobic drug (PPHD) and bee pollen (BP), for which
the relevant methods of quality control (MQC) were developed.
Substance BP is a nely dispersed powder from white
to brown colour, depending on the plants from which bees
collect nectar, which includes a large number of proteins,
carbohydrates, lipids, nucleic acids, mineral elements and
other biologically important substances [8]. In addition, BP
composition includes essential amino acids and essential
unsaturated fatty acids – linoleic and linolenic, which quantities
is more than half of the total amount of these compounds.
Phospholipids of bee pollen are represented with cho-
line-phosphoglicerides (lecithins) inositophosphoglicerides,
etanolaminophosphoglicerides (cephalins), phosphatidylseri-
nes and other compounds that make up the semi dense cell
membranes of animal and humans organisms that selectively
regulate ow of ions to the cells and are actively involved
in metabolism. Showing the properties of substances with
lipotropic action phospholipids promote the emergence slow-
down and excessive accumulation of fat and its deposition in
the cells, especially liver tissue, which prevents fatty liver and
atherosclerosis [8].
The presence of a signicant amount of phytosterols,
carbohydrates, enzymes, nucleic and triterpene acids, vita-
mins and other biologically active substances in BP provides
anti-inammatory, wound healing, cardiotonic, antiatheroscle-
rotic and other pharmacological actions.
Thus, the data above indicate the prospects of new highly
ecient drugs for the treatment of chronic prostatitis and pro-
state gland adenoma based on biologically active standardized
substances of bee products, including powdered honey (PH)
PPHD and BP in order to replenish the pharmaceutical market
of Ukraine with new national drugs.
The aim of this work was the discussion of the obtained
results of conducted preclinical pharmacological studies
of the new national drug of natural origin for the treatment
Original research

644
Запорожский медицинский журнал. Том 19, № 5(104), сентябрь–октябрь 2017 г.ISSN 2306-4145 http://zmj.zsmu.edu.ua
of diseases of the genitourinary system, including prostatitis
and prostate gland adenoma.
Materials and methods
The objects of research were standardized substances of bee
products – PH, PPHD and BP and their mixture as the API
composition that are the part of the developed drug.
Powdered honey (PH) (TC U 10.8-39834691-001:2015
«Honey powdered») [12,13]. The dry, ne powder without
impurities, dry, smooth consistency and pleasant taste without
other avours and smells, homogeneous throughout the mass
with dierent shades of colour depending on the raw material.
Mass fraction of moisture and volatile substances is
less than 8.0 %. Mass share of renewable carbohydrates (to
anhydrous substance) is not less than 70.0 %. Mass fraction
of sucrose (to anhydrous substance) is less than 6.0 %.
Diastase number Goethe units (calculated on the anhydrous
substance) is at least 15.0. 5-hydroxymethylfurfurol content
(calculated on dry residue) is less than 0.008 % (80 ppm).
Acidity (milliequivalents of sodium hydroxide 0.1 mol/dm 3)
is less than 50.0 per 1 kg. The content of proline (calculated
on the anhydrous substance) is not less than 0.03 %. Mass
fraction of ash is not more than 7.0 %. Size of grinding: sieve
residue on the number of wire mesh N. 067 is less than
1.0 %. Mass fraction of impurities: metallomagnetic (the size
of the largest linear dimension of less than 0.3 mm) is less
than 3∙10
-4
; mineral, not soluble in hydrochloric acid, is less
than 1.0 %; vegetable – is not allowed.
MP is obtained from natural honey by the method of ac-
tivation drying by YUVET technologies [14] or by the method
of freeze-drying (moisture release from the frozen solution)
using authorized for the use excipients [13].
The substance comes in powder form designed for usage
in pharmaceutical, perfumery and cosmetic, and food indu-
stries and must meet the developed and approved by the rele-
vant authorities requirements ТC U 10.8–39834691–001:2015
«Powdered honey» [13].
Propolis phenolic hydrophobic drug (PPHD) (Praeparatum
Propolis phenohydrophobum) – (RC № UA/4505/01/01, Order
MH Ukraine № 337 from 07.06.2011, PhA 42У-34-20-95, AND-
DV-GF-090, Specication SPC-PP-77. Producer: «Zdorovya»
Pharmaceutical company, Ltd. (Kharkiv, Ukraine) [2].
PPHD is hydrophobic powder of reddish-brown colour,
specic odour, soluble in 96 % alcohol P, practically insoluble
in water P, petroleum ether P, chloroform P. Content of phenolic
compounds calculated on the dry matter should be at least
50.0 %. The loss in weight on drying is not more than 3.0 %,
heavy metals are less than 0.001 %.
The main BAS of PPHD that cause its pharmacological
eects are phenolic compounds, including apigenin, luteolin,
kaempferol, quercetin, robidanol and others [7].
Bee pollen (ower pollen) – (DSTU 3127-95) (AND-DR-
ZT-DF-029) (for the incoming control). Producer: «Zdorovya»
Pharmaceutical company, Ltd. (Kharkiv, Ukraine) (Order MH
Ukraine from 23.05.2008 № 273. RC № UA/8194/01/01) [2].
The collected by bees pollen has a dense texture in
the form of lumps. They are solid in consistency, with irregular
shape, weight from 5 to 20 mg, colour from light yellow to
brown, a specic characteristic smell, sweet taste, the concen-
tration of hydrogen ions (pH) of 2 % aqueous solution product
is (4.3–5.3 ) – 4.7. The chemical composition of the collected
pollen diers signicantly from collecting pollen and is cha-
racterized by a high content of various groups of biologically
active compounds [8].
Study of preclinical pharmacological research of the de-
veloped drug was conducted at the Central Research Labo-
ratory of the National University of Pharmacy.
Considering that chronic prostatitis and prostate gland are
often accompanied by inammation and pain during studying
of specic pharmacological activity of standardized substances
mixture of bee products (PH, PPHD and BP) to establish the ef-
fective dose of the composition there was selected the model
of acute inammation exudative carrageenen foot inammation
in rats [15]. Various mediators of inammation are involved in
the mechanism carrageenen edema, according to Di Rosa et
al. [16] in the rst 30–90 minutes in the pathogenesis of edema
is caused by histamine and serotonin, in the range between
1.5–2.5 h – by kinines, and between 2.5–5.5 h – by prosta-
glandins. The range of mediators involved in the development
of the process of exudation in this model allows to assume
the mechanism of action of the studied substances.
Experiments were carried out on rats weighing 150–170 g.
Edema of the foot was caused with subplantare introduction
into the right hind paw 0.1 ml 1 % solution of carrageenen
manufactured by Serva. The composition of standardized
substances of PH, PPHD and BP was administered in doses
5, 30, 60 і 100 mg/kg. Voltaren gel was used as the reference
drug with anti-inammatory action at a dose of 8 mg/kg (LD
50
by antiexudative eect in this model) [17]. Diclofenac sodium
is widely used in the clinic of internal diseases accompanied
by inammation [18]. The studied drug and the reference drug
were administered intragastrically one hour before the injec-
tion of ohogenic agent. Animals of the control pathology
group received adequate to their mass quantity of water. The
development of edema was registered by the increase of paws
volume, which was measured in the dynamics through 1, 2,
3, 5, 24 hour with onkometre by Zaharevskyy A. S. [19,20].
Anti-inammatory activity was determined by the degree
of reduction of edema in animals treated with drugs compared
with animals of control pathology group and expressed as a
percentage. The results of the experiment were calculated
according to the formula presented in Fig. 1:
A (% oppression) =
V
k
– V
0
× 100 %,
V
k
where V
k
– the average value of paw volume in the group
of control pathology;
V
0
– the average value of paw volume in the groups
treated with the composition of standardized substances.
In view of the established dynamic antiexudative action
of standardized substances of bee products composition it can
be assumed that their BAS are relatively quickly absorbed into
the bloodstream and eliminated relatively slowly, which may
contribute to the treatment of acute and chronic inammation
typical for prostatitis.
In this regard, it became feasible to conduct a study of an-
tiprostatic activity to study the eect of the composition of API
(PH, PPHD and BP) mixture on the course of experimental
prostatitis, which was were carried out on a model of acute
prostatitis in rats caused by dichloroethyl [21].
For screening there were chosen the following doses –
50, 100, 130 and 170 mg/kg. As a reference drug the medical
analogue – trianom capsules – were used at a dose of 6 mg/kg,
Оригинальные исследования

645
Zaporozhye medical journal. Volume 19. No. 5, September–October 2017 ISSN 2306-4145 http://zmj.zsmu.edu.ua
which was calculated using the coecient of species stability
by Rybolovlev [16]. Active substance of trianom capsules is
an active lipid-sterol complex of herbal origin.
Outbred white male rats weighing 250–290 g were used in
experiment. On day 10 of the experiment blood was taken in
rats from the tail vein for clinical analysis. After the procedure
the rats were decapitated under ether anesthesia. Vesicles
glands were weighed, and their weight coecient was calcu-
lated. In serum and prostate homogenate malondialdehyde
content was determined because it is known that the system
is activated lipid peroxidation when prostatitis [22]. Results
obtained are presented in Table 1.
Results and their discussion
Analysis of the obtained results, presented in Fig. 1, shows
that the most eective anti-inammatory composition of AFI
mixture reveals at a dose of 100 mg/kg. The average an-
ti-inammatory activity of the mixture of PH, PPHD and BP
at the dose 100 mg/kg was 40 % during the experiment. In
the given dose the drug signicantly reduced the development
of edema during the experiment compared to the control
pathology group, but its activity did not exceed the anti-inam-
matory eects of diclofenac sodium, which also signicantly
reduced edema during the experiment.
Considering the data set by Di Rosa [16], about the es-
tablished sequence of inammatory mediators changes in
this pathology model it can be assumed that the mechanism
of anti-inammatory action of standardized substances of bee
products is based on their ability to inhibit the synthesis of pro-
staglandins, which are important in the treatment of prostate
diseases, which are often accompanied by pain syndrome [23].
It is also possible to suggest that eect is the result of complex
action of avonoids, which are present in the API mixture com-
position, on cells and enzymes resposible for the development
of inammation. It is known that phenolic compounds exhibit
antioxidant properties [24], in connection with what ability of mix-
ture PH, PPHD and BP to block induction of lipid peroxidation,
which occurs during inammation, is related [25].
The results presented in Table 1 show that under experi-
mental pathology in rats following signs of inammation were
observed. On the 10
th
day after the alteration in the prostate
gland areas of necrosis, purulent discharge, reduction
of weight of vesicles glands were observed.
In conditions of treatment with the composition of stan-
dardized substances of bee products in doses of 100 and
130 mg/kg, trianom capsules, likely reduction in leucocytes
level in the blood and the likely increase of weight coecient
of vesicle glands were observed, prostate gland was of normal
type form without cell necrosis in the most animals. Local ac-
tivation of lipid peroxidation and reduced antioxidant capacity
in prostate gland tissue play an important pathogenic role in
the development of chronic prostatitis.
The pathology was characterized by the increased levels
of MDA in blood serum and prostate homogenate, indicating
the activation of lipid peroxidation and the development
of inammation. Analysis of the results obtained in groups
of animals treated with standardized substances of PH,
PPHD and BP composition in doses of 100 and 130 mg/kg
showed probable reduction of malondialdehyde in prostate
homogenate compared to the control pathology group. In
the group of animals treated standardized substances of PH,
PPHD and BP composition in doses of 100 and 130 mg/kg
MDA levels in serum compared with the control pathology
group signicantly reduced. Group of animals treated with
trianom in the dose of 6 mg/kg, also showed a likely reduction
in leucocytes in the blood, malondialdehyde in serum and
prostate homogenate, the likely increase of weight coe-
cient of vesicles gland compared with the control pathology
group.
Thus, in condition experimental prostatitis composition
of standardized substances of bee products – PH, PPHD and
BP, in the dose of 100 mg/kg, it was revealed a pronounced
therapeutic eect at the level of the reference drug – trianom
capsules.
Conclusions
1. The application of bee products to create a new drug
on their basis in the form of standardized substances of bee
products composition – PH, PPHD and BP for chronic pro-
statitis and prostate gland adenoma was grounded.
Control Mixture of API 30 mg/kg
Diclofenac sodium
Mixture of API 100 mg/kg
Mixture of API 60 mg/kg
t, hours
Size of edema, conv. un.
20
18
16
14
12
10
8
6
4
2
0
12345
Fig. 1. Screening for anti-inammatory activity of standardized substances of bee products
composition – PH, PPHD and BP.
Table 1. The results of screening studies of antiprostatic activity of standardized substances of bee products composition – PH, PPHD and BP (n = 6)
Indicator Groups of animals
Intact control Control patholgy Trianol
6 mg/kg
The mixture API
50 mg/kg
The mixture API
100 mg/kg
The mixture API
130 mg/kg
x ± Sx
Leucocytes, 109/l 14.55 ± 1.81 22.30 ± 1.40* 12.56 ± 1.31** 17.60 ± 1.67 12.85 ± 1.64** 14.05 ± 1.75**
MDA in serum, mmol/l 0.29 ± 0.03 0.72 ± 0.11* 0.44 ± 0.04** 0.59 ± 0.19 0.4 ± 0.03** 0.61 ± 0.09
MDA in prostate homognate, mmol/g 25.64 ± 2.69 46.66 ± 3.59* 24.61 ± 3.02** 44.36 ± 6.02 27.43 ± 3.52** 25.32 ± 3.12**
Weight coecient of vescles gland 1.14 ± 0.10 0.42 ± 0.04* 0.80 ± 0.04*/** 0.53 ± 0.07*/*** 0.54 ± 0.03*/**/*** 0.60 ± 0,04*/**/***
*: probable deviations in relation to the intact control group, p < 0.05; **: probable deviations relative to the control pathology group, p < 0.05;
***: probable deviations in relation to the reference drug group (trianom), p < 0.05.
Original research

646
Запорожский медицинский журнал. Том 19, № 5(104), сентябрь–октябрь 2017 г.ISSN 2306-4145 http://zmj.zsmu.edu.ua
2. It was found that the most pronounced anti-inammato-
ry eect on 40 % level detects the mix-ture of API (PH, PPHD
and BP) at the dose of 100 mg/kg.
3. It was established that the composition of standardized
substances of bee products –PH, PPHD and BP, ta the dose
of 100 mg/kg shows maximally pronounced specic pharma-
cological eect related to the reference drug – trianol capsules
at the doses of 100 and 130 mg/kg, which posi-tively aects
the course of experimental prostatitis in male rats caused by
dichlorethyle.
Perspectives of further scientic research. Com-
position of standardized substances of bee products – PH,
PPHD and BP, are a promising source for development of new
domestic drugs for use in urological practice. The presented
results of the studies conrm the necessity of continuation
of this composition research with the purpose of subsequent
introduction of the obtained medicine into medical practice.
References
[1] Arslanov, M. M., Kamalov, I. I., & Fattakhov, V. V. (2011) Fizioterapev-
ticheskie metody lecheniya khronicheskogo prostatita [Physiotherapy
treatment of chronic prostatitis]. Prakticheskaya medicina, 1(49), 22–24.
[in Russian].
[2] Sharykina, N. I. (Ed) (2013) Derzhavnyi reiestr likarskykh zasobiv
Ukrainy. Kyiv. Retrieved from http://www.drlz.kiev.ua. [in Ukrainian].
[3] Solihov, D. N. (2009) Vobenzim v lechenii khronicheskogo bakterial’no-
go prostatita [Vobenzim and treatment of chronic prostatitis]. Doklady
akademii nauk Respubliki Tadzhikistan, 52(5), 400–402. [in Russian].
[4] Bratchikov, O. I., Shestakov, S. G., Shumakova, E. A., & Makhov, S. V.
(2008) The increase of clinico-immunological eciency in complex
therapy of patients with chronic prostatitis. Urology, 2, 44–49.
[5] Al’-Shukri, S. Kh., Petlenko, S. V., Borovets, S. Yu., Rybalov, M. A.,
Soroka, I. V., & Stukan’, N. I. (2016) Eect of Prostatilene
®
AC and
Prostatilene
®
on the ejaculate level of antisperm antibodies in the treat-
ment of patients with chronic abacterial prostatitis and concomitant
reproductive dysfunctions. Andrology and genital surgery, 1(17), 40–43.
doi: http://dx.doi.org/10.17650/2070-9781-2016-17-1-40-43.
[6] Tikhonov, A. I., Tikhonova, S. A., Yarnykh, T. G., Shpychak, O. S., et al.
(2010) Med natural’nyj v medicine i farmacii (proiskhozhdenie, svojstva,
primenenie, lekarstvennye preparaty) [Honey natural in medicine and
pharmacy (origin, properties, applications, medicinal products)]. Kharkiv:
Original. [in Russian].
[7] Tichonov, A. I., Jarnych, T. G., Czernych, W. P. et al. (2005) Teoria i prak-
tyka wytwarzania leczniczych preparatow propolisowych. Kraków: Marka.
[8] Tichonow, A. I., Sodzawiczny, K., Tichonowa, S. A., Jarnych, T. G.,
Bondarczuk, L. I., & Kotenko, A. M. (2008) Pylek kwiatowy obnoze
pszczele w farmacji i medycynie. Teoria, technologia, zastosowanie
lecznicze. Kraków: Apipol-Pharma.
[9] Shpychak, O. S. (2016) Teoretychne ta eksperymentalne obhruntuvannia
skladu і rozrobka tehnolohіi lіkarskykh apіpreparatіv dlia zastosuvannia
u sportyvnіi medytsynі. (Avtoref. dis… dokt. farm. nauk) [Theoretical
and experimental study of composition and development of medical
technology apipreparativ for use in sports medicine Dr. fharm. sci. diss.].
Kharkiv. [in Ukrainian].
[10] Shpychak, О. S., Tykhonov, O. I., Zupanets, I. A., & Shebeko, S. K.
(2015) The experimental study of the anti-inammatory properties
of combined aerosols with the propolis phenolic hydrophobic drug. The
Pharma Innovation, 3(11), 26-29.
[11] Shpychak, О. S., Tykhonov, O. I., Zupanets, I. A., Shebeko, S. K.
(2015) The study of the analgesic properties of combined aerosols with
the propolis phenolic hydrophobic drug in the experiment. The Pharma
Innovation, 4(3), 78-81.
[12] Spychak, O. S., Tykhonov, O. I., Kotov, A. H., et al. (2014) Med [Honey].
Derzhavna farmakopeia Ukrainy, (Vol. 2), (P. 436–439). Kharkiv: Der-
zhavne pidpryiemstvo «Ukrainskyi naukovyi farmakopeinyi tsentr yakosti
likarskykh zasobiv» [in Ukrainian].
[13] Tykhonov, O. I., Yudin, O. I., Yarnykh, T. H., Shpychak, O. S., et al. (2015)
TUU 10.8–39834691–001:2015 Med poroshkopodibnyi [Powdered
honey]. Kyiv. [in Ukrainian].
[14] Yudin, O. I. (2010) Innovacionnye tekhnologii i konstruktivnye osoben-
nosti oborudovaniya dlya polucheniya pischevykh poroshkov [Innovative
technologies and design features of equipment for obtaining food
powders]. Kharkiv. [in Russian].
[15] Stefanov, O. V. (Ed) (2001) Doklinichni doslidzhennia likarskykh zasobiv
[Preclinical studies of drugs]. Kyiv: Avіtsenna. [in Ukrainian].
[16] Yakovleva, L. V. (1992) Poisk i izuchenie novykh NPVP – proizvodnykh
dikarbonovykh kislot (Dis… dokt. farm. nauk) [Search and study of new
NSAID – derivatives of dicarboxylic acids. Dr. farm. sci. diss.] Kharkiv.
[in Russian].
[17] Kovalenko, V. N. (Ed) (2017) Kompendium 2015 – lekarstvennye prepa-
raty [Compendium 2016 – medicines]. Kyiv: MORION. [in Russian].
[18] Karateev, A. E., Uspensky, Yu. P., Pakhomova, I. G., & Nasonov, E. L.
(2012) Kratkij kurs istorii NPVP [A concise course of the history of NSAIDs].
Nauchno-prakticheskaya revmatologiya, 3(52), 101–106. [in Russian].
[19] Zaharevskij, A. S. (1962) Vliyanie nekotorykh proizvodnykh indola na
nervnuyu sistemu (Dis…kand. med. nauk) [Inuence of some indole
derivatives on the nervous system. Dr. med. sci. diss. Minsk. [in Russian].
[20] Shpychak, О. S., & Tikhonov, O. I. (2014) Eksperymentalne dos-
lidzhennia spetsychnoi farmakolohichnoi dii kombinovanoho heliu
«Artproment» [The experimental study of the specic pharmacological
action of «Artproment®» combined gel]. Zaporozhye medical journal,,
4(85), 103–106. [in Ukrainian].
[21] Lar’yanovskaya, Yu. B., Dranova, I. N., Kishinec, N. V., Dzyuba, I. P., &
Butenko, I. G. (1999) Holodovaya travma predstatel’noj zhelezy krysy kak
e´ksperimental’naya model’ prostatita [Cold injury of the prostate gland
of the rat as an experimental model of prostatitis]. Proceedings of the V Na-
tional Congress of Pharmacists of Ukraine. Kharkiv: Prapor. [in Russian].
[22] Bomko, T. V., Maslova, N. F., Kozlova, N. G., Dolgaya, I. N., & Pyati-
kop, A. B. (2002) Famakologicheskoe izuchenie suppozitoriev s maslom
semyan tykvy na modeli e´ksperimental’nogo prostatita [Pharmacological
study of suppositories with pumpkin seed oil on the model of experimen-
tal prostatitis]. Visnyk farmatsii, 2(30), 90–92. [in Russian].
[23] Gus`kov, A. R. (2008) Istoki khronicheskogo prostatita [The origins
of chronic prostatitis]. Moscow: Medica. [in Russian].
[24] Bent, H. H. (2002) The biochemistry and medical significance
of the avonoids. Pharmacology and Therapeutics, 96(2–3), 167–202.
doi: 10.1016/S0163-7258(02)00298-X.
[25] Serov, V. V., & Paukov, V. S. (1995) Vospalenie. Rukovodstvo dlya vrachej
[Inammation. Guidlines for doctors]. Moscow: Medicina. [in Russian].
Information about authors:
Koval V. M., Candidate of Pharmaceutical Sciences, Associate
Professor of the Department of Pharmacy of the National Pirogov
Memorial Medical University, Vinnytsia, Ukraine.
Tykhonov O. I., Doctor of Pharmaceutical Sciences, Professor
of the Department of Technology of Perfumes and Cosmetics
of the National University of Pharmacy, Kharkiv, Ukraine, Honored
Worker of Science and Technology of Ukraine, Honored Inventor
of the USSR.
Shpychak O. S., Doctor of Pharmaceutical Sciences, Associate
Professor of the Drug Technology Department of the National
University of Pharmacy, Kharkiv, Ukraine.
Відомості про авторів:
Коваль В. М., канд. фарм. наук, доцент каф. фармації,
Вінницький національний медичний університет
імені М. І. Пирогова, Україна.
Тихонов О. І., д-р фарм. наук, професор каф. технології
парфумерно-косметичних засобів, Національний
фармацевтичний університет, м. Харків, Україна, заслужений
діяч науки і техніки України, заслужений винахідник СРСР.
Шпичак О. С., д-р фарм. наук, доцент каф. аптечної технології ліків,
Національний фармацевтичний університет, м. Харків, Україна.
Cведения об авторах:
Коваль В. Н., канд. фарм. наук, доцент каф. фармации,
Винницкий национальный медицинский университет
имени Н. И. Пирогова, Украина.
Тихонов А. И., д-р фарм. наук, профессор каф. технологии
парфюмерно-косметических средств, Национальный
фармацевтический университет, г. Харьков, Украина,
заслуженный деятель науки и техники Украины, заслуженный
изобретатель СССР.
Шпичак О. С., д-р фарм. наук, доцент каф. аптечной технологии
лекарств, Национальный фармацевтический университет,
г. Харьков, Украина.
Конфлікт інтересів: відсутній.
Conicts of Interest: authors have no conict of interest to declare.
Надійшло до редакції / Received: 04.05.2017
Після доопрацювання / Revised: 12.05.2017
Прийнято до друку / Accepted: 25.05.2017
Оригинальные исследования